A detailed history of Vanguard Group Inc transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,110,795 shares of CRBU stock, worth $6.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,110,795
Previous 3,962,044 3.75%
Holding current value
$6.74 Million
Previous $22.7 Million 6.93%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$4.82 - $8.26 $716,979 - $1.23 Million
148,751 Added 3.75%
4,110,795 $21.1 Million
Q4 2023

Feb 14, 2024

BUY
$3.58 - $6.25 $500,816 - $874,331
139,893 Added 3.66%
3,962,044 $22.7 Million
Q3 2023

Nov 14, 2023

BUY
$4.08 - $8.14 $5.15 Million - $10.3 Million
1,261,920 Added 49.29%
3,822,151 $18.3 Million
Q2 2023

Aug 14, 2023

SELL
$4.04 - $5.47 $185,153 - $250,690
-45,830 Reduced 1.76%
2,560,231 $10.9 Million
Q1 2023

May 15, 2023

BUY
$4.3 - $7.78 $111,129 - $201,066
25,844 Added 1.0%
2,606,061 $13.8 Million
Q4 2022

Feb 10, 2023

BUY
$5.57 - $11.01 $149,214 - $294,946
26,789 Added 1.05%
2,580,217 $16.2 Million
Q3 2022

Nov 14, 2022

BUY
$5.34 - $12.79 $3 Million - $7.18 Million
561,065 Added 28.16%
2,553,428 $26.9 Million
Q2 2022

Aug 12, 2022

SELL
$5.1 - $9.74 $46,874 - $89,520
-9,191 Reduced 0.46%
1,992,363 $10.8 Million
Q1 2022

May 13, 2022

BUY
$8.42 - $15.32 $9.15 Million - $16.7 Million
1,087,038 Added 118.86%
2,001,554 $18.4 Million
Q4 2021

Feb 14, 2022

SELL
$14.59 - $23.26 $319,287 - $509,021
-21,884 Reduced 2.34%
914,516 $13.8 Million
Q3 2021

Nov 12, 2021

BUY
$15.75 - $30.29 $14.7 Million - $28.4 Million
936,400 New
936,400 $22.4 Million

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $99.8M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.